Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 244 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Eicosapentaenoic Acid Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Kansas University DHA Outcome Study (KUDOS) Follow-Up

NCT02487771
View directory record Official record
Conditions
Pregnancy
Interventions
DHA, Placebo Capsule
Drug
Lead sponsor
Susan Carlson, PhD
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults

NCT03043365
View directory record Official record
Conditions
Lipoprotein Metabolism, PCSK9, Proteomics
Interventions
control fish oil, LCMUFA-rich saury oil
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Not applicable Interventional

Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients

NCT01154400
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Casein protein hydrolysates, Whey protein hydrolysates, Casein protein hydrolysates + LEU, Whey protein hydrolysates + LEU
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 1 Interventional

Cord Blood Plus Vitamin D and Omega 3s in T1D

NCT00873925
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Autologous UCB, Omega 3 FA, Vitamin D
Biological · Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

NCT01486433
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin, acetylsalicylic acid (ASA), omefas
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 3, 2026, 4:50 PM EDT
Withdrawn Phase 2 Interventional

OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer

NCT03661047
View directory record Official record
Conditions
Colon Cancer
Interventions
AMR101 (VASCEPA, icosapent ethyl)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Not applicable Interventional

Memory Improvement With Docosahexaenoic Acid Study (MIDAS)

NCT00278135
View directory record Official record
Conditions
Age-Related Cognitive Decline, Age-Related Memory Disorders
Interventions
DHA (nutritional supplement) or placebo
Dietary Supplement
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
55 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
14
States / cities
Mesa, Arizona • San Diego, California • Vista, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral, Genetic, and Epigenetic Implications of Dietary Supplementation With Alpha-linolenic Acid in Humans

NCT01634776
View directory record Official record
Conditions
Effect of Fatty Acids on Memory Performance of Toddlers
Interventions
Flaxseed oil, corn oil
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Months to 16 Months
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

NCT00351533
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Fish oil (eicosapentaenoic acid and docosahexanoic acid)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)

NCT01747447
View directory record Official record
Conditions
Bone Density, Body Composition, Bone Health
Interventions
Vitamin D3 placebo, Fish oil placebo, omega-3 fatty acids (fish oil), Vitamin D3
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
771 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 3, 2026, 4:50 PM EDT
Terminated Phase 3 Interventional Results available

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

NCT00944229
View directory record Official record
Conditions
Heart Failure
Interventions
LOVAZA (Omega-3), Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Not applicable Interventional Results available

High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions

NCT01814527
View directory record Official record
Conditions
Mild Concussion, Brain Concussion, Cerebral Concussion
Interventions
Docosahexaenoic acid, Placebo
Dietary Supplement · Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 40 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vascepa to Accelerate Lipoprotein Uptake and Elimination

NCT03885661
View directory record Official record
Conditions
Lipid Disorder, Triglycerides High, Dyslipidemias
Interventions
Icosapent Ethyl 1000 MG [Vascepa]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain

NCT01351805
View directory record Official record
Conditions
Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis
Interventions
Fish Oil, Vitamin D, placebo pill
Drug · Dietary Supplement · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure

NCT01534663
View directory record Official record
Conditions
Heart Failure
Interventions
Glutamine and Fish Oil Supplementation, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects

NCT03750968
View directory record Official record
Conditions
Nutrient Deficiency, Pregnancy Related
Interventions
Carotenoid Group, Control Group
Drug · Dietary Supplement
Lead sponsor
Paul S. Bernstein
Other
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Evaluation of Cow Milk-Based Formulas

NCT00518414
View directory record Official record
Conditions
Term Infants
Interventions
Marketed infant formula with DHA and ARA, Milk-based infant formula with DHA and ARA, Milk-based formula with DHA, ARA, prebiotics
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
10 Days to 18 Days
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Tamarac, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Corneal Nerves Function and Structure

NCT04222660
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Blackmores Omega Daily (4 1g capsules per day)
Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Not applicable Interventional

Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

NCT01200446
View directory record Official record
Conditions
Asthma
Interventions
Docosahexaenoic Acid, Placebo Docosahexaenoic Acid
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 3 Interventional

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

NCT00146211
View directory record Official record
Conditions
Huntington Disease
Interventions
Ethyl-EPA (Miraxion™)
Drug
Lead sponsor
Amarin Neuroscience Ltd
Industry
Eligibility
35 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 3, 2026, 4:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 3, 2026, 4:50 PM EDT